Literature DB >> 24996839

MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.

Paul Ravi Waldron1, Mark Holodniy2.   

Abstract

Investigations into the role of microRNA (miRNA) in hepatitis C virus (HCV) infection, disease pathogenesis and host immune and treatment response have potential to produce innovations in diagnosis, prognosis and therapy. However, investigational challenges remain in generating clinically useful and reproducible results. We review the literature with a primary emphasis on methods and technologies used to construct our current understanding of miRNA and HCV disease. A second emphasis is to understand potential clinical research applications and provide clarification of previous study results. Many miRNA have key roles in viral and immunopathogenesis of HCV infection across multiple tissue compartments. Controversy exists among published studies regarding relative measurements, temporal changes and biological significance of specific miRNA and HCV infection. To reconcile diverging data, additional research into optimal sample processing, in vitro models, techniques for microarray differential expression of miRNAs, practices for sample result normalization, and effect of HCV genotype variation on expression are all necessary. Microarray and miRNA isolation techniques should be selected based on ability to generate reproducible results in the sample type of interest. More direct comparisons of efficacy and reliability of various multiplex microarrays and an improved consensus around miRNA normalization and quantitation are necessary so that data can be compared across studies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiviral agents; Hepatitis C; Inflammation; MicroRNA; Rxeview

Mesh:

Substances:

Year:  2014        PMID: 24996839      PMCID: PMC4368430          DOI: 10.1016/j.diagmicrobio.2014.05.024

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  90 in total

1.  Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods.

Authors:  Maria Eldh; Jan Lötvall; Carina Malmhäll; Karin Ekström
Journal:  Mol Immunol       Date:  2012-04       Impact factor: 4.407

2.  Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans.

Authors:  Rebecca T Marquez; Sarmistha Bandyopadhyay; Erik B Wendlandt; Kathy Keck; Brandon A Hoffer; Michael S Icardi; Randolph N Christensen; Warren N Schmidt; Anton P McCaffrey
Journal:  Lab Invest       Date:  2010-07-12       Impact factor: 5.662

Review 3.  Roles of microRNAs in the life cycles of mammalian viruses.

Authors:  Eva Gottwein
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

4.  Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.

Authors:  Hisashi Ishida; Tomohide Tatsumi; Atsushi Hosui; Takatoshi Nawa; Takahiro Kodama; Satoshi Shimizu; Hayato Hikita; Naoki Hiramatsu; Tatsuya Kanto; Norio Hayashi; Tetsuo Takehara
Journal:  Biochem Biophys Res Commun       Date:  2011-07-23       Impact factor: 3.575

5.  Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.

Authors:  Joydip Bhanja Chowdhury; Shubham Shrivastava; Robert Steele; Adrian M Di Bisceglie; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Interferon modulation of cellular microRNAs as an antiviral mechanism.

Authors:  Irene M Pedersen; Guofeng Cheng; Stefan Wieland; Stefano Volinia; Carlo M Croce; Francis V Chisari; Michael David
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

8.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

9.  Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia.

Authors:  Flavien Bernardin; Leslie Tobler; Irina Walsh; Joan Dunn Williams; Mike Busch; Eric Delwart
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

10.  Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array.

Authors:  Bin Wang; Paul Howel; Skjalg Bruheim; Jingfang Ju; Laurie B Owen; Oystein Fodstad; Yaguang Xi
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

View more
  3 in total

1.  Internal driving factors leading to extrahepatic manifestation of the hepatitis C virus infection.

Authors:  Zhou-Yi Wu; Jian-Rui Li; Meng-Hao Huang; Jun-Jun Cheng; Hu Li; Jin-Hua Chen; Xiao-Qin Lv; Zong-Gen Peng; Jian-Dong Jiang
Journal:  Int J Mol Med       Date:  2017-10-05       Impact factor: 4.101

Review 2.  Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis.

Authors:  Emmanuel Albuquerque-Souza; Sinem E Sahingur
Journal:  Periodontol 2000       Date:  2022-03-04       Impact factor: 12.239

3.  miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling.

Authors:  Hui Tian; Zhenkun He
Journal:  Yonsei Med J       Date:  2018-06       Impact factor: 3.052

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.